ACE and stage 5 chronic kidney disease: Despite superior BUN levels and improved antiproteinuric and antifibrotic potential of dual blockade (as shown in Figure 2, Figure 3 and Figure 4), lifespan prior to end-stage renal failure was not significantly improved by dual therapy (ACE+Spiro) with a mean survival of 89.3 ± 17.6 days (Figure 5).